FDA Classifies Drug Response Testers as Class II Medical Devices
Published Date: 8/21/2025
Rule
Summary
The FDA is officially putting the pharmacogenetic assessment system into a special safety category called Class II. This means the device will have clear rules to keep it safe and effective, helping patients get access to cool new medical tech faster. If you make or use these devices, get ready for some updated guidelines that balance safety with easier approval.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Patients: Easier Access to Pharmacogenetics
The FDA is classifying the pharmacogenetic assessment system into Class II (special controls). The agency says this classification will provide a reasonable assurance of safety and effectiveness and will enhance patients' access to these devices by reducing regulatory burdens.
Device Makers: New Class II Controls
Manufacturers of pharmacogenetic assessment systems will see the device type classified into Class II with special controls that will be codified in regulation. The FDA says this action will provide reasonable assurance of safety and effectiveness and will reduce regulatory burdens.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in